Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) Enterprise Value (2016 - 2025)

Regenxbio (RGNX) has 12 years of Enterprise Value data on record, last reported at -$230.1 million in Q4 2025.

  • For Q4 2025, Enterprise Value rose 1.97% year-over-year to -$230.1 million; the TTM value through Dec 2025 reached -$230.1 million, up 1.97%, while the annual FY2025 figure was -$230.1 million, 1.97% up from the prior year.
  • Enterprise Value reached -$230.1 million in Q4 2025 per RGNX's latest filing, up from -$274.2 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$230.1 million in Q4 2025 and bottomed at -$457.4 million in Q4 2021.
  • Average Enterprise Value over 5 years is -$330.0 million, with a median of -$327.6 million recorded in 2023.
  • Peak YoY movement for Enterprise Value: plummeted 57.88% in 2021, then rose 24.51% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$457.4 million in 2021, then increased by 20.29% to -$364.6 million in 2022, then grew by 24.51% to -$275.3 million in 2023, then grew by 14.74% to -$234.7 million in 2024, then grew by 1.97% to -$230.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$230.1 million in Q4 2025, -$274.2 million in Q3 2025, and -$323.3 million in Q2 2025.